«Need for more sensitive
lung cancer screening criteria, study suggests.»
Not exact matches
Still, the authors say this study «indicates that
lung cancer screening can be cost - effective in a population - based setting if stringent smoking eligibility
criteria are applied.»
An analysis of
lung cancer incidence and
screening found a decline in the proportion of patients with
lung cancer meeting high - risk
screening criteria, suggesting that an increasing number of patients with
lung cancer would not have been candidates for
screening, according to a study in the February 24 issue of JAMA.
Though the optimal scenario is actually estimated to catch fewer
lung cancers than the criteria used in the National Lung Screening Trial (NLST) in the US, the authors predict this more stringent scenario would require fewer CT scans, and lead to fewer false positive screens and lung cancer overdiagnosis, which can lead to patient h
lung cancers than the
criteria used in the National
Lung Screening Trial (NLST) in the US, the authors predict this more stringent scenario would require fewer CT scans, and lead to fewer false positive screens and lung cancer overdiagnosis, which can lead to patient h
Lung Screening Trial (NLST) in the US, the authors predict this more stringent scenario would require fewer CT scans, and lead to fewer false positive
screens and
lung cancer overdiagnosis, which can lead to patient h
lung cancer overdiagnosis, which can lead to patient harm.
Ping Yang M.D., Ph.D., of the Mayo Clinic, Rochester, Minn., and colleagues conducted a study to examine the trends in the proportion of patients with
lung cancer meeting the USPSTF
screening criteria.
«Less inclusive
criteria for
lung cancer screening would be cost - effective.»
Inclusion
Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small cell
lung cancer (NSCLC)(Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation
Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at
Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta - human chorionic gonadotropin [beta - hCG]-RRB- at
Screening within 14 days prior to study drug administration Inclusion
Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.
Commenting on the significance of the research, Dr Pilar Garrido, head of the Thoracic Tumour Section of the Medical Oncology Department at Ramón y Cajal University Hospital, Madrid, Spain, said: «
Lung cancer is the most common
cancer globally, but debate about the optimal
screening strategy is ongoing and current selection
criteria are based only on age and pack - years.